Exploring the Evolution of Statin Pricing in Australia: Observations of Price Disclosure Effects on Pharmaceutical Benefits Scheme Expenditure.

Value Health Reg Issues

Centre for Applied Health Economics, School of Medicine and Dentistry, Griffith University, Southport, Australia.

Published: March 2024

Objectives: The high cardiovascular disease burden globally and in Australia necessitates attention on statin expenditure, the primary pharmacological intervention for cardiovascular disease risk factors. The Pharmaceutical Benefits Scheme (PBS) subsidies approved statins for Australians. Managing PBS government expenditure occurs through price control strategies of statutory price decreases upon first generic entry and price disclosure. This study investigates the impact price control measures had on statin price evolution and government expenditure between 2010 and 2022.

Methods: Prescription and pricing data were obtained from Services Australia Medicare Statistics, and price reduction strategies from the PBS. Summary statistics compared and described statin price, prescription, number of brands, market share, and government expenditure to atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin price control timelines.

Results: Statin prices exposed to price control measures decreased irrespective of dosage and correlated with reductions in government expenditure, with a comparison of 2010 and 2022 showing annual statin expenditure declined by AU$833.5 million (83.25%) whereas prescriptions reduced by 3.0 million (15.7%). Effects of price disclosure on atorvastatin and rosuvastatin market share suggest industry-prompted price reductions may arise from market share loss, whereas reasons external to pricing prompted rosuvastatin to gain market share.

Conclusions: Limited publications on contemporary effects of statin price control measures exist. This investigation found these measures reduced government expenditure for statins by AU$949.1 million, with the price reduction correlating with price control measures. In addition to affirming price control mechanisms remain effective in contemporary times, this investigation provides data for key insights into the Australian statin industry.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vhri.2023.10.004DOI Listing

Publication Analysis

Top Keywords

price control
28
government expenditure
20
price
16
control measures
16
price disclosure
12
statin price
12
market share
12
statin
8
pharmaceutical benefits
8
benefits scheme
8

Similar Publications

Purpose: Radiotherapy (RT) for oropharyngeal cancer (OPC) can lead to late toxicity. Fatigue is a known debilitating issue for many cancer survivors, yet prevalence and severity of long-term fatigue in patients treated for OPC is unknown.

Method: As part of a mixed-methods study, fatigue in OPC patients ≥ 2 years post RT + / - chemotherapy was evaluated.

View Article and Find Full Text PDF

Objectives: To investigate the epidemiological characteristics and changing trends of communicable diseases among children and adolescents in China from 1990 to 2021.

Methods: Based on the Global Burden of Disease Database, epidemiological indicators for communicable diseases among the population aged under 20 years in China from 1990 to 2021 were selected to analyze the burden of communicable diseases in this population, and a comparative analysis was performed with global data as well as data from Western Europe and North America.

Results: In 1990-2021, the overall burden of communicable diseases tended to decrease among children and adolescents in China.

View Article and Find Full Text PDF

The promise of AI in healthcare: transforming communication and decision-making for patients.

J Commun Healthc

January 2025

Venditti Consulting, LLC, Westport, CT, United States.

By addressing communication gaps, the integration of AI tools in healthcare has a greater ability to improve decision-making and to empower patients with more control over their health. Current systems for navigating healthcare - such as finding providers or understanding costs - are fragmented and cumbersome, often leaving patients frustrated and uninformed. An AI Healthcare Assistant App, leveraging advances in health IT interoperability, price transparency, and user-centred design, could simplify these processes.

View Article and Find Full Text PDF

Background: Women involved in the criminal legal system have elevated rates of opioid use disorder, which is treatable, and HIV, which is preventable with pre-exposure prophylaxis (PrEP). There are significant social and structural barriers to integrated delivery of PrEP and medications for opioid use disorder (MOUD), limiting women's ability to access these life-saving interventions. In a two parallel-arm randomized controlled trial, we are assessing an innovative eHealth delivery model that integrates PrEP with MOUD and is tailored to meet the specific needs of women involved in the criminal legal system.

View Article and Find Full Text PDF

We aimed to evaluate the effects of prepartum supplementation of different I sources (Ascophyllum nodosum [ASCO] meal and ethylenediamine dihydroiodide [EDDI]) on colostrum yield of cows, and blood concentrations of glucose, BHB, and thyroid hormones and growth of dairy calves. Forty multiparous Holstein cows were blocked by lactation number and expected calving date and assigned to 1 of 4 treatments 28 d before parturition: (1) EDDI supplemented (11 mg/d) to a basal diet to meet the NRC (2001) I concentration of 0.5 mg of I/kg of DMI (control = CON [0 g/d of ASCO meal]; actual I concentration = 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!